[da inserire]
-
May 20, 2019 (v1)PublicationUploaded on: April 14, 2023
-
2017 (v1)Publication
Many evidences suggest that NK cells are effective in patrolling for and eliminating tumors in their onset phase, but hardly limit the progression of large established solid tumors. Beside the transition of tumor cells towards a more aggressive phenotype, the NK cell efficacy might be limited by a complex immunosuppressive milieu present in the...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Activity of human natural killer (NK) cells against cancer cells is deeply suppressed by TGF-beta1, an immunomodulatory cytokine that is released and activated in the tumor microenvironment. Moreover, our previous data showed that TGF-beta1 modifies the chemokine receptor repertoire of NK cells. In particular, it decreases the expression of...
Uploaded on: March 27, 2023 -
2017 (v1)Publication
Angiogenesis represents a hallmark of tumor progression in Multiple Myeloma (MM), a still incurable malignancy. Here we analyzed the activity of cytokine-stimulated NK cells against tumor-associated endothelial cells isolated from bone marrow aspirates of MM patients with active disease (MMECs). We show that NK cells activated with optimal...
Uploaded on: March 27, 2023 -
2017 (v1)Publication
Tyrosine kinase inhibitors (TKIs) are used in the clinical management of hematological neoplasms. Moreover, in solid tumors such as stage 4 neuroblastomas (NB), imatinib showed benefits that might depend on both on-target and immunological off-target effects. We investigated the effects of imatinib and nilotinib on human NK cells, monocytes,...
Uploaded on: April 14, 2023